NASDAQ:KZRKezar Life Sciences Stock Price, Forecast & News

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KZR shares have increased by 31.6% and is now trading at $5.25. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kezar Life Sciences.

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Kezar Life Sciences.

Kezar Life Sciences Inc (NASDAQ:KZR) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.07. View Kezar Life Sciences' earnings history.

4 brokers have issued 1 year price targets for Kezar Life Sciences' stock. Their forecasts range from $12.00 to $18.00. On average, they expect Kezar Life Sciences' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price. View analysts' price targets for Kezar Life Sciences.

News articles about KZR stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Kezar Life Sciences.

Some companies that are related to Kezar Life Sciences include Endo International (ENDP), Dynavax Technologies (DVAX), Morphic (MORF), Kura Oncology (KURA), Stoke Therapeutics (STOK), Assembly Biosciences (ASMB), Kadmon (KDMN), Applied Therapeutics (APLT), Frequency Therapeutics (FREQ), ZIOPHARM Oncology (ZIOP), Homology Medicines (FIXX), Passage Bio (KROS), RAPT Therapeutics (RAPT), Provention Bio (PRVB) and Eagle Pharmaceuticals (EGRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Opko Health (OPK), Gilead Sciences (GILD), ADMA Biologics (ADMA), Agile Therapeutics (AGRX), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Aptinyx (APTX), Clovis Oncology (CLVS) and Crispr Therapeutics (CRSP).

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $5.25.

Kezar Life Sciences has a market capitalization of $200.43 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]